NO20025975D0 - Purinderivater - Google Patents

Purinderivater

Info

Publication number: NO20025975D0
Authority: NO; Norway
Prior art keywords: purine derivatives; purine; derivatives
Prior art date: 2000-06-27

Application number

NO20025975A

Other languages

English (en)

Norwegian (no)

Other versions

NO20025975L (no

Inventor

Simon John Mantell

Sandra Marina Monaghan

Peter Thomas Stephenson

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-06-27

Filing date

2002-12-12

Publication date

2002-12-12

2002-12-12 Application filed by Pfizer filed Critical Pfizer

2002-12-12 Publication of NO20025975D0 publication Critical patent/NO20025975D0/no

2002-12-12 Publication of NO20025975L publication Critical patent/NO20025975L/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pulmonology (AREA)
Reproductive Health (AREA)
Cardiology (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Gynecology & Obstetrics (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Pain & Pain Management (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Psychiatry (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Hematology (AREA)
Pregnancy & Childbirth (AREA)
Oncology (AREA)
Obesity (AREA)
Rheumatology (AREA)

NO20025975A 2000-06-27 2002-12-12 Purinderivater NO20025975L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0015727.1A GB0015727D0 (en)	2000-06-27	2000-06-27	Purine derivatives
PCT/IB2001/001064 WO2002000676A1 (en)	2000-06-27	2001-06-14	Purine derivatives

Publications (2)

Publication Number	Publication Date
NO20025975D0 true NO20025975D0 (no)	2002-12-12
NO20025975L NO20025975L (no)	2002-12-12

Family

ID=9894500

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20025975A NO20025975L (no)	2000-06-27	2002-12-12	Purinderivater

Country Status (42)

Country	Link
EP (1)	EP1296996B1 (xx)
JP (1)	JP2004501929A (xx)
KR (1)	KR20030036248A (xx)
CN (1)	CN1432020A (xx)
AP (1)	AP1372A (xx)
AR (1)	AR028759A1 (xx)
AT (1)	ATE267836T1 (xx)
AU (1)	AU2001264164A1 (xx)
BG (1)	BG107171A (xx)
BR (1)	BR0111912A (xx)
CA (1)	CA2412564C (xx)
CZ (1)	CZ20023992A3 (xx)
DE (1)	DE60103537T2 (xx)
DK (1)	DK1296996T3 (xx)
DO (1)	DOP2001000195A (xx)
EA (1)	EA200201291A1 (xx)
EC (1)	ECSP024396A (xx)
EE (1)	EE200200712A (xx)
ES (1)	ES2220775T3 (xx)
GB (1)	GB0015727D0 (xx)
GT (1)	GT200100119A (xx)
HR (1)	HRP20020995A2 (xx)
HU (1)	HUP0301389A3 (xx)
IL (1)	IL152529A0 (xx)
IS (1)	IS6580A (xx)
MA (1)	MA26918A1 (xx)
MX (1)	MXPA03000078A (xx)
NO (1)	NO20025975L (xx)
NZ (1)	NZ521867A (xx)
OA (1)	OA12294A (xx)
PA (1)	PA8521001A1 (xx)
PE (1)	PE20020213A1 (xx)
PL (1)	PL361384A1 (xx)
PT (1)	PT1296996E (xx)
SI (1)	SI1296996T1 (xx)
SK (1)	SK17332002A3 (xx)
SV (1)	SV2002000507A (xx)
TN (1)	TNSN01096A1 (xx)
TR (1)	TR200401622T4 (xx)
UY (1)	UY26797A1 (xx)
WO (1)	WO2002000676A1 (xx)
ZA (1)	ZA200209557B (xx)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE60215028T2 (de)	2001-08-14	2007-03-15	Eli Lilly And Co., Indianapolis	Indol derivate als beta-3-adrenerge agonisten zur behandlung von typ 2 diabetes
SE0201980D0 (sv) *	2002-06-24	2002-06-24	Astrazeneca Ab	Novel compounds
WO2004028530A1 (en)	2002-09-26	2004-04-08	Bristol-Myers Squibb Company	N-substituted heterocyclic amines as modulators of chemokine receptor activity
AR044519A1 (es)	2003-05-02	2005-09-14	Novartis Ag	Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
GB0401334D0 (en)	2004-01-21	2004-02-25	Novartis Ag	Organic compounds
GB0411056D0 (en)	2004-05-18	2004-06-23	Novartis Ag	Organic compounds
PE20060272A1 (es)	2004-05-24	2006-05-22	Glaxo Group Ltd	(2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
BRPI0515506A (pt) *	2004-09-20	2008-07-29	Inotek Pharmaceuticals Corp	derivados de purina e métodos de uso dos mesmos
GB0424284D0 (en)	2004-11-02	2004-12-01	Novartis Ag	Organic compounds
GB0426164D0 (en)	2004-11-29	2004-12-29	Novartis Ag	Organic compounds
GB0510390D0 (en)	2005-05-20	2005-06-29	Novartis Ag	Organic compounds
GB0514809D0 (en)	2005-07-19	2005-08-24	Glaxo Group Ltd	Compounds
MY144906A (en)	2005-10-21	2011-11-30	Novartis Ag	Human antibodies against il13 and therapeutic uses
GB0601951D0 (en)	2006-01-31	2006-03-15	Novartis Ag	Organic compounds
RU2457209C2 (ru) *	2006-04-21	2012-07-27	Новартис Аг	Производные пурина, предназначенные для применения в качестве агонистов аденозинового рецептора а2а
US7589076B2 (en) *	2006-05-18	2009-09-15	Pgx Health, Llc	Substituted aryl piperidinylalkynyladenosines as A2AR agonists
MX2009003185A (es)	2006-09-29	2009-04-03	Novartis Ag	Pirazolopirimidinas como inhibidores de lipido cinasa pi3k.
AU2007315234A1 (en)	2006-10-30	2008-05-08	Novartis Ag	Heterocyclic compounds as antiinflammatory agents
US7897737B2 (en)	2006-12-05	2011-03-01	Lasergen, Inc.	3′-OH unblocked, nucleotides and nucleosides, base modified with photocleavable, terminating groups and methods for their use in DNA sequencing
CN101910153B (zh)	2008-01-11	2014-01-22	诺华股份有限公司	作为激酶抑制剂的嘧啶类
KR101677772B1 (ko) *	2008-06-11	2016-11-18	레이저젠, 인코퍼레이티드	뉴클레오타이드 및 뉴클레오사이드 그리고 시퀀싱에서의 이들의 이용 방법
PT2391366E (pt)	2009-01-29	2013-02-05	Novartis Ag	Benzimidazoles substituídos para o tratamento de astrocitomas
US8389526B2 (en)	2009-08-07	2013-03-05	Novartis Ag	3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
BR112012003262A8 (pt)	2009-08-12	2016-05-17	Novartis Ag	compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação
PE20121148A1 (es)	2009-08-17	2012-09-07	Intellikine Llc	Compuestos heterociclicos y usos de los mismos
UY33597A (es)	2010-09-09	2012-04-30	Irm Llc	Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (en)	2010-09-09	2012-03-15	Irm Llc	Compounds and compositions as trk inhibitors
EP2673277A1 (en)	2011-02-10	2013-12-18	Novartis AG	[1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
JP5808826B2 (ja)	2011-02-23	2015-11-10	インテリカイン，エルエルシー	複素環化合物およびその使用
BR112013021638A2 (pt)	2011-02-25	2016-08-02	Irm Llc	"compostos inibidores de trk, seu uso e composições que os compreendem"
EP2755976B1 (en)	2011-09-15	2018-07-18	Novartis AG	6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyridines as c-met tyrosine kinase inhibitors
US20130209543A1 (en)	2011-11-23	2013-08-15	Intellikine Llc	Enhanced treatment regimens using mtor inhibitors
JP2015512425A (ja)	2012-04-03	2015-04-27	ノバルティスアーゲー	チロシンキナーゼ阻害剤との組合せ製品及びそれらの使用
WO2014151147A1 (en)	2013-03-15	2014-09-25	Intellikine, Llc	Combination of kinase inhibitors and uses thereof
WO2015084804A1 (en)	2013-12-03	2015-06-11	Novartis Ag	Combination of mdm2 inhibitor and braf inhibitor and their use
WO2016011658A1 (en)	2014-07-25	2016-01-28	Novartis Ag	Combination therapy
AU2015294889B2 (en)	2014-07-31	2018-03-15	Novartis Ag	Combination therapy
US12324807B2 (en)	2018-06-01	2025-06-10	Cornell University	Combination therapy for PI3K-associated disease or disorder
TW202140550A (zh)	2020-01-29	2021-11-01	瑞士商諾華公司	使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1988003147A1 (en) *	1986-10-31	1988-05-05	Warner-Lambert Company	Selected n6-substituted adenosines having selective a2 binding activity
IL107101A0 (en) *	1992-09-30	1993-12-28	Merrell Dow Pharma	2-substituted adenosines with a-2 receptor affinity
GB9723590D0 (en) *	1997-11-08	1998-01-07	Glaxo Group Ltd	Chemical compounds
CA2317093A1 (en) *	1998-01-08	1999-07-15	Joel M. Linden	A2a adenosine receptor agonists
AU5879299A (en) *	1998-10-16	2000-05-08	Monaghan, Sandra Marina	Adenine derivatives
GB9913932D0 (en) *	1999-06-15	1999-08-18	Pfizer Ltd	Purine derivatives
GB9924363D0 (en) *	1999-10-14	1999-12-15	Pfizer Central Res	Purine derivatives
GB9924361D0 (en) *	1999-10-14	1999-12-15	Pfizer Ltd	Purine derivatives

2000
- 2000-06-27 GB GBGB0015727.1A patent/GB0015727D0/en not_active Ceased
2001
- 2001-06-14 OA OA1200200387A patent/OA12294A/en unknown
- 2001-06-14 AU AU2001264164A patent/AU2001264164A1/en not_active Abandoned
- 2001-06-14 PT PT01938490T patent/PT1296996E/pt unknown
- 2001-06-14 SI SI200130136T patent/SI1296996T1/xx unknown
- 2001-06-14 JP JP2002505798A patent/JP2004501929A/ja active Pending
- 2001-06-14 KR KR1020027017723A patent/KR20030036248A/ko not_active Ceased
- 2001-06-14 NZ NZ521867A patent/NZ521867A/en unknown
- 2001-06-14 AT AT01938490T patent/ATE267836T1/de not_active IP Right Cessation
- 2001-06-14 WO PCT/IB2001/001064 patent/WO2002000676A1/en not_active Ceased
- 2001-06-14 ES ES01938490T patent/ES2220775T3/es not_active Expired - Lifetime
- 2001-06-14 BR BR0111912-5A patent/BR0111912A/pt not_active IP Right Cessation
- 2001-06-14 DE DE60103537T patent/DE60103537T2/de not_active Expired - Fee Related
- 2001-06-14 TR TR2004/01622T patent/TR200401622T4/xx unknown
- 2001-06-14 MX MXPA03000078A patent/MXPA03000078A/es active IP Right Grant
- 2001-06-14 EA EA200201291A patent/EA200201291A1/ru unknown
- 2001-06-14 CN CN01810621A patent/CN1432020A/zh active Pending
- 2001-06-14 CZ CZ20023992A patent/CZ20023992A3/cs unknown
- 2001-06-14 CA CA002412564A patent/CA2412564C/en not_active Expired - Fee Related
- 2001-06-14 EP EP01938490A patent/EP1296996B1/en not_active Expired - Lifetime
- 2001-06-14 EE EEP200200712A patent/EE200200712A/xx unknown
- 2001-06-14 HR HR20020995A patent/HRP20020995A2/hr not_active Application Discontinuation
- 2001-06-14 DK DK01938490T patent/DK1296996T3/da active
- 2001-06-14 HU HU0301389A patent/HUP0301389A3/hu unknown
- 2001-06-14 IL IL15252901A patent/IL152529A0/xx unknown
- 2001-06-14 SK SK1733-2002A patent/SK17332002A3/sk unknown
- 2001-06-14 PL PL36138401A patent/PL361384A1/xx not_active Application Discontinuation
- 2001-06-21 AP APAP/P/2001/002193A patent/AP1372A/en active
- 2001-06-21 GT GT200100119A patent/GT200100119A/es unknown
- 2001-06-22 DO DO2001000195A patent/DOP2001000195A/es unknown
- 2001-06-25 PA PA20018521001A patent/PA8521001A1/es unknown
- 2001-06-25 PE PE2001000615A patent/PE20020213A1/es not_active Application Discontinuation
- 2001-06-26 AR ARP010103038A patent/AR028759A1/es unknown
- 2001-06-26 UY UY26797A patent/UY26797A1/es not_active Application Discontinuation
- 2001-06-26 TN TNTNSN01096A patent/TNSN01096A1/fr unknown
- 2001-06-26 SV SV2001000507A patent/SV2002000507A/es not_active Application Discontinuation
2002
- 2002-10-07 BG BG107171A patent/BG107171A/xx unknown
- 2002-10-10 IS IS6580A patent/IS6580A/is unknown
- 2002-11-25 ZA ZA200209557A patent/ZA200209557B/en unknown
- 2002-12-12 NO NO20025975A patent/NO20025975L/no not_active Application Discontinuation
- 2002-12-19 EC EC2002004396A patent/ECSP024396A/es unknown
- 2002-12-20 MA MA26970A patent/MA26918A1/fr unknown

Also Published As

Publication number	Publication date
IL152529A0 (en)	2003-05-29
CZ20023992A3 (cs)	2003-12-17
AU2001264164A1 (en)	2002-01-08
CA2412564C (en)	2007-10-02
EA200201291A1 (ru)	2003-04-24
NZ521867A (en)	2004-04-30
HUP0301389A2 (hu)	2003-08-28
HUP0301389A3 (en)	2005-02-28
DE60103537T2 (de)	2005-07-07
EP1296996B1 (en)	2004-05-26
KR20030036248A (ko)	2003-05-09
AR028759A1 (es)	2003-05-21
ZA200209557B (en)	2003-12-02
CA2412564A1 (en)	2002-01-03
UY26797A1 (es)	2002-01-31
BR0111912A (pt)	2003-05-13
TR200401622T4 (tr)	2004-08-23
DOP2001000195A (es)	2002-05-15
GB0015727D0 (en)	2000-08-16
SV2002000507A (es)	2002-07-03
EE200200712A (et)	2004-06-15
BG107171A (en)	2003-07-31
GT200100119A (es)	2002-01-31
PA8521001A1 (es)	2002-04-25
PL361384A1 (en)	2004-10-04
AP1372A (en)	2005-02-21
ECSP024396A (es)	2003-02-06
ES2220775T3 (es)	2004-12-16
IS6580A (is)	2002-10-10
PE20020213A1 (es)	2002-03-19
HRP20020995A2 (en)	2005-02-28
DE60103537D1 (de)	2004-07-01
SK17332002A3 (sk)	2004-03-02
NO20025975L (no)	2002-12-12
DK1296996T3 (da)	2004-08-16
SI1296996T1 (en)	2004-10-31
PT1296996E (pt)	2004-08-31
MXPA03000078A (es)	2003-08-19
EP1296996A1 (en)	2003-04-02
JP2004501929A (ja)	2004-01-22
ATE267836T1 (de)	2004-06-15
MA26918A1 (fr)	2004-12-20
OA12294A (en)	2003-11-14
CN1432020A (zh)	2003-07-23
WO2002000676A1 (en)	2002-01-03
TNSN01096A1 (fr)	2005-11-10

Publication	Publication Date	Title
DE60119492D1 (de)	2006-06-14	Purinderivate
DE60103537D1 (de)	2004-07-01	Purinderivate
ATE431356T1 (de)	2009-05-15	2-aminocarbonyl-9h-purinderivative
DE60116260D1 (de)	2006-02-02	Antivirale azaindolderivate
ATE321065T1 (de)	2006-04-15	Purin-derivate
DK1220863T3 (da)	2003-08-11	Purinderivater
EE200100681A (et)	2003-04-15	Puriinderivaadid
DE60130463D1 (de)	2007-10-25	Pyrimidin-derivate
DK1280809T3 (da)	2005-11-07	Antitumorecteinascidinderivater
ATE298332T1 (de)	2005-07-15	Decahydro-isochinolinderivate
DK1322593T3 (da)	2004-10-11	O-substituerede-6-methyl-tramadol-derivater
DK1246791T3 (da)	2005-02-14	Aminomethyl-phenyl-cyklohexanonderivater
ATE374776T1 (de)	2007-10-15	Pyrrolotriazolopyrimidinonderivate
NO20024393D0 (no)	2002-09-13	2-fenylpyran-4-on-derivater
EP1295891A4 (en)	2004-05-26	Nucleoside derivatives

Legal Events

Date	Code	Title	Description
2006-01-30	FC2A	Withdrawal, rejection or dismissal of laid open patent application